Diabetes & Metabolism
Diabetes mellitus and hypertension are two of the most common diseases in Westernized, industrialized civilizations, and the frequency of both diseases increases with increasing age. Diabetes mellitus is characterized by elevated blood glucose levels (hyperglycemia) resulting from defects in insulin secretion, insulin action or both, and associated with a considerably increased cardiovascular risk, peripheral vascular diseases, stroke, retinopathy, and nephropathy. Two types of diabetes mellitus are recognized based on the presumed etiology. In type 1 diabetes, the body fails to produce insulin as a result of an auto-immune reaction that destroys the islet cells in the pancreas that produce insulin, and daily insulin injections are required. Type 1 diabetes is usually diagnosed during childhood or early adolescence and it affects about 1 in every 600 children. Type 2 diabetes is the result of failure to produce sufficient insulin and insulin resistance. Elevated blood glucose levels are managed with reduced food intake, increased physical activity, and eventually oral medications or insulin. Type 2 diabetes is typically diagnosed during adulthood. However with the increasing incidence of childhood obesity and concurrent insulin resistance, the number of children diagnosed with type 2 diabetes has also increased worldwide.
The hallmark of hypertension in type I and type II diabetics appears to be increased peripheral vascular resistance. Increased exchangeable sodium may also play a role in the pathogenesis of blood pressure in diabetics. Evidence is accumulating that insulin resistance, or hyperinsulinemia, may play a key role in the pathogenesis of hypertension in both subtle and overt abnormalities of carbohydrate metabolism. Population studies suggest that elevated insulin levels, which often occurs in type II diabetes mellitus, is an independent risk factor for cardiovascular disease. Other cardiovascular risk factors in diabetic individuals include abnormalities of lipid metabolism, platelet function, and clotting factors.
Axon ID | Name | Description | From price | |
---|---|---|---|---|
2340 | AZ-GHS-22 | Orally available Ghrelin receptor (GHS-R1a) inverse agonist | €160.00 | |
2147 | CpdD hydrochloride | Ghrelin receptor (GhrR aka GHSR-1a) antagonist | €135.00 | |
2727 | Elafibranor | Dual PPARα/δ agonist | €90.00 | |
2686 | FH535 | Dual inhibitor of PPAR and Wnt/β-catenin signaling | €75.00 | |
2706 | FH535 sodium salt | Dual inhibitor of PPAR and Wnt/β-catenin signaling | €80.00 | |
2363 | GSK 2033 | The first potent cell-active LXR antagonist | €105.00 | |
1628 | GSK 3787 | PPARδ antagonist | €90.00 | |
1266 | GW 3965 hydrochloride | Liver X receptor agonist | €95.00 | |
2262 | GW 9662 | Selective PPARγ antagonist | €60.00 | |
2019 | INT131 | Selective PPARγ modulator (partial agonist) | €90.00 | |
1567 | KRP 297 | PPARα agonist; PPARγ agonist | €110.00 | |
2357 | LXR 623 | Partial agonist of Liver X Receptor | €95.00 | |
2814 | MHY 553 | PPARα agonist | €95.00 | |
2402 | MHY 908 | Dual PPARα/γ agonist, and potent inhibitor of mushroom tyrosinase | €95.00 | |
1376 | MK 677 | Growth hormone secretagogue (GHS) agonist | €80.00 | |
3739 | RGX-104 | Liver X receptor (LXR) agonist | Inquire | |
3999 | Saroglitazar magnesium | Potent dual PPARα/γ agonist | €160.00 | |
2807 | SPA70 | Potent and selective human pregnane X receptor (hPXR) antagonist | €125.00 | |
2598 | SR 9243 | LXR inverse agonist inhibiting the Warburg effect and lipogenesis in cancer cells | €85.00 | |
2754 | T0901317 | Liver X receptor (LXR) agonist | €75.00 | |
3486 | TM-N1324 | Highly potent and selective GPR39 agonist | €110.00 | |
1991 | WYE 672 | Liver X receptor (LXR) agonist | €120.00 |